TrialVaccine2021

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.

Joel V Chua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.